AbbVie Inc. (0QCV.L)
| Previous close | 80.48 |
| Open | 104.39 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 104.39 - 104.39 |
| 52-week range | 104.39 - 104.39 |
| Volume | 400 |
| Avg. volume | N/A |
| Market cap | 133.665B |
| Beta (5Y monthly) | 0.83 |
| PE ratio (TTM) | 24.17 |
| EPS (TTM) | 3.71 |
| Earnings date | 29 Oct 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Investor's Business Daily Video
Option Trade: Increase Your Income With This Covered Call Strategy
For today's trade, we're looking at a covered call in AbbVie stock. With markets looking shaky, investors looking to increase their income can use covered calls and cash secured puts on high dividend stocks.
- Simply Wall St.
Downward Pressures and Flat Earnings Outweigh the AbbVie Inc.'s (NYSE:ABBV) Dividend Yield
AbbVie Inc. (NYSE: ABBV) recently cratered, as modest yearly gains almost got wiped out in a single session. Meanwhile, downward pressure continues as the price looks to test the support around US$100 for the third time this year. We will examine the dividend as the stock dips down below the P/E of 30 since a 4.8% yield is certainly interesting at the right price.
- Business Wire
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
COPENHAGEN, Denmark & NORTH CHICAGO, Ill., September 09, 2021--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced The Lancet published the results of the dose escalation part of the phase 1/2 EPCORE™ NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical trial evaluating safety and preliminary efficacy of the investigational therapy epcoritamab (DuoBody®-CD3xCD20) in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL). The full manuscript is a
